| Literature DB >> 33555988 |
Yuzhong Li1, Yanwei Bi1, Hongjian Xiao1, Yueting Yao1, Xiaojuan Liu1, Zhengrong Hu1, Jinmei Duan1, Yaoyun Yang1, Zhihua Li1, Yadong Li1, Heng Zhang1, Chen Ding1, Jianbo Yang1, Haiwei Li1, Zhanlong He1, Longding Liu1, Guangnan Hu2, Shuying Liu3, Yanchun Che1, Shixia Wang2, Qihan Li1, Shan Lu2, Wei Cun1.
Abstract
The current study aims to develop a safe and highly immunogenic COVID-19 vaccine. The novel combination of a DNA vaccine encoding the full-length Spike (S) protein of SARS-CoV-2 and a recombinant S1 protein vaccine induced high level neutralizing antibody and T cell immune responses in both small and large animal models. More significantly, the co-delivery of DNA and protein components at the same time elicited full protection against intratracheal challenge of SARS-CoV-2 viruses in immunized rhesus macaques. As both DNA and protein vaccines have been proven safe in previous human studies, and DNA vaccines are capable of eliciting germinal center B cell development, which is critical for high-affinity memory B cell responses, the DNA and protein co-delivery vaccine approach has great potential to serve as a safe and effective approach to develop COVID-19 vaccines that provide long-term protection.Entities:
Keywords: DNA vaccine; SARS-CoV-2; non-human primate; protein vaccine; spike glycoprotein
Mesh:
Substances:
Year: 2021 PMID: 33555988 PMCID: PMC7928010 DOI: 10.1080/22221751.2021.1887767
Source DB: PubMed Journal: Emerg Microbes Infect ISSN: 2222-1751 Impact factor: 7.163